Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the Uni... (Investor Relations section of the Transc...)

HOME >> BIOLOGY >> TECHNOLOGY

Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States

Date:8/2/2009

Investor Relations section of the Transcept website at www.transcept.com. A replay of the call will be available on the website shortly after the conclusion of the call until Monday, September 7, 2009.

Date: Monday, August 3, 2009

Time: 8:30 a.m. ET

Dial-in (U.S.): 877-545-1490

Dial-in (International): 719-325-4864

A telephone replay of the conference call will be available beginning August 3, 2009 at 11:30 a.m. ET and ending on August 17, 2009. The replay telephone number is 888-203-1112 (U.S.) or 719-457-0820 (International), Replay Passcode: 5541799.

Transcept Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to expectations with respect to the launch and market potential of Intermezzo((R)); expectations with respect to the activities of Transcept and Purdue and the satisfaction of conditions under the United States License and Collaboration Agreement (Collaboration Agreement); expectations regarding potential milestone payments and royalties under the Collaboration Agreement; the timing of regulatory decisions with respect to the NDA for Intermezzo((R)) with the FDA; expectations for use of proceeds that may be obtained pursuant to the Collaboration Agreement; plans of Transcept to exercise the option to co-promote Intermezzo((R)) and to develop a specialty sales force; plans of Purdue to make a significant U.S. primary care marketing investment and prioritize Intermezzo((R)) commercialization; Intermezzo(
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.; Purdue Pharmaceutical Products L.P.
Copyright©2009 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4 5 6 7
Related biology technology :

1. Purdue creating wireless sensors to monitor bearings in jet engines
2. Purdue leads center to simulate behavior of micro-electromechanical systems
3. Purdue Pharma L.P. Announces Resolution of OxyContin(R) Patent Lawsuit with Mallinckrodt Inc.
4. Purdue researcher invents molecule that stops SARS
5. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
6. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results

Post Your Comments:

(Date:12/16/2009)... BioSciences, LLC introduces HSP-A Soy Peptone. HSP A has been ... , ... (PRWEB) December 16, 2009 -- Nu-Tek BioSciences, LLC. ... introducing HSP-A Soy Peptone. HSP-A, previously manufactured by Nutricepts, Inc. ... proven to improve growth rates and yields. HSP-A has been ...

(Date:12/15/2009)... Dec. 15 Epeius Biotechnologies Corporation, an ... medicine, gained international validation of the cutting-edge science ... when scientists around the world rediscovered the ... locus of cancer pathogenesis and disease progression, and ... scientists at the NIH National Cancer Institute investigating ...

(Date:12/15/2009)... Mass., Dec. 15 Repligen Corporation (Nasdaq: ... has received $731,000 in research funding to support ... ataxia from the Muscular Dystrophy Association (MDA). ... GLP toxicology testing and GMP manufacture of a ... from the MDA not only provides important funding ...

(Date:12/15/2009)... 15 Reportlinker.com announces that a ... its catalogue: ,, The Future ... to 2015, Pipeline Analysis and Reimbursement ... ,, Summary ,, The ... Future of Orphan Diseases Therapeutics - Market ...

[0] Nu-Tek BioSciences, LLC. Launches Animal-Free, Non-GM Soy Peptone [0] Scientists Rediscover Gene Target for Cancer Therapy [0] Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreich's Ataxia Preclinical Development Program [0] Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement

... PLC, a,subsidiary of MGT Capital Investments, Inc. (Amex: ... development of Computer-Aided Detection (CAD) and image,analysis software ... of,disease, announces a new global partnership with INFINITT, ... archiving and communication,systems (PACS) companies. Combined INFINITT-Medicsight products ...

... SAN DIEGO, April 7, 2008 Ardea Biosciences,Inc. ... will be presented on its,second generation non-nucleoside reverse ... Antiviral Research (ICAR).,Additionally, data on two of the ... will be presented at the American,Association for Cancer ...

... Sangamo,BioSciences, Inc. (Nasdaq: SGMO ) today announced ... Open Monoclonal Technologies (OMT), a private,company based in ... a non-exclusive, worldwide license to OMT for the ... zinc finger,DNA-binding protein (ZFP) technology. OMT will pay ...

Other Biology Technology:Medicsight Announces New Marketing Partnership with INFINITT 2 Medicsight Announces New Marketing Partnership with INFINITT 3 Ardea to Present Data on HIV Non-Nucleoside Reverse Transcriptase Inhibitor and Two MEK Inhibitors at Upcoming Medical Conferences 2 Ardea to Present Data on HIV Non-Nucleoside Reverse Transcriptase Inhibitor and Two MEK Inhibitors at Upcoming Medical Conferences 3 Sangamo BioSciences Announces License Agreement For the Use of ZFP Technology For Generation of Transgenic Animals 2 Sangamo BioSciences Announces License Agreement For the Use of ZFP Technology For Generation of Transgenic Animals 3

Medicsight Announces New Marketing Partnership with INFINITT Ardea to Present Data on HIV Non-Nucleoside Reverse Transcriptase Inhibitor and Two MEK Inhibitors at Upcoming Medical Conferences Sangamo BioSciences Announces License Agreement For the Use of ZFP Technology For Generation of Transgenic Animals

(Date:12/16/2009)... of financial and technical assistance to developing countries around ... to be connected to space technology, but large development ... linked. , Global climate change is also an increasingly ... the poorest countries and communities, which will suffer the ... to a growing demand for information about the state ...

(Date:12/16/2009)... inhabited our planet for more than 4 billion years ... by as many eons more. That suggests they may ... Tel Aviv University bacteria expert Prof. Eshel Ben-Jacob of ... Astronomy, grounded in the study of bacteria, presents compelling ... most people should not automatically opt for the swine ...

(Date:12/16/2009)... 1 GestureTek Inc. today announced ... - a turnkey, portable, plug and play ... entertainment and touring promotions. GestureTek is the ... in camera-enabled gesture recognition technology for interactive ... for quality, the CUBE has TUV, CE, ...

Breaking Biology News(10 mins):ESA and World Bank move toward closer collaboration 2 ESA and World Bank move toward closer collaboration 3 ESA and World Bank move toward closer collaboration 4 Bacteria wouldn't opt for a swine flu shot 2 Bacteria wouldn't opt for a swine flu shot 3 GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits 2 GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits 3 Self destructing bacteria improve renewable biofuel production 11024 1 Self destructing bacteria improve renewable biofuel production 11024 2 Self destructing bacteria improve renewable biofuel production 11024 3 City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec 5 to 8 in New Orleans 62792 1 City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec 5 to 8 in New Orleans 62792 2 City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec 5 to 8 in New Orleans 62792 3 City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec 5 to 8 in New Orleans 62792 4 City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec 5 to 8 in New Orleans 62792 5 VitaminSpice Signs Agreement With Former CEO of Wal Mart Stores Division for US Distribution 62788 1 VitaminSpice Signs Agreement With Former CEO of Wal Mart Stores Division for US Distribution 62788 2

[0] ESA and World Bank move toward closer collaboration [0] Bacteria wouldn't opt for a swine flu shot [0] GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits

... rocks are more abundant and diverse than previously thought, ... to results of a study reported in this week,s ... pose intriguing questions about ocean chemistry and the co-evolution ... plain dotted with hydrothermal vents, the seafloor,s rocky regions ...

... floor, microbial life is feeding on fresh volcanic rock ... optimistic scientists thought possible. According to a study published ... bacteria growing on oceanic crust in concentrations that are ... magnitude) greater than what is found in the overlying ...

... symbiotic gut bacteria may offer a new type of ... the California Institute of Technology. , "Most people ... only make us sick," says Sarkis K. Mazmanian, an ... the symbiotic relationship between "good" bacteria and their mammalian ...

Other Biology News:Bacteria 'feed' on earth's ocean-bottom crust 2 Scientists find bacteria thriving on a feast of seafloor rock 2 Getting better with a little help from our 'micro' friends 2 Getting better with a little help from our 'micro' friends 3

Bacteria 'feed' on earth's ocean-bottom crust Scientists find bacteria thriving on a feast of seafloor rock Getting better with a little help from our 'micro' friends

... Assay with SR-101 Labeled Substrates (red ... Accurately measure serine protease activation • ... B-Bridge's FLISP Kits utilize cell-permeable, fluorescently ... to measure chymotrypsin-like activity in whole ...

... array systems, known as ChemiArrayTM Mouse ... compared with current methodologies. Besides the ... systems present a more accurate reflection ... only detect secreted cytokines, and no ...

... Easy Cap tool provides the firm ... double-locking caps in tubes or plates. ... wide end that firmly holds thin-wall ... crushing when opening or closing. A ...

... is a highly nutritious versatile medium which ... to the inclusion of both Tryptone and ... of many fastidious organisms without the addition ... United States Pharmacopeia standards for use in ...

Biology Products:

SR-101 FLISP FLISP Leu-CMK Assay Kit from B-Bridge International ChemiArray Mouse Lysate Angiogenesis Antibody Array I , 25 cytokines per membrane from CHEMICON Easy Cap Tool from Bio-Rad Tryptic Soy Agar powder (USP) from Mo Bio Laboratories, Inc.

Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the Uni...(Investor Relations section of the Transc...)